RESUMEN
BACKGROUND: Renally adjusted lamivudine dosages are effective. However, some of the kidney failure patients managed with lamivudine-containing regimens are failing to suppress HIV in peritoneal dialysis (CAPD) effluent. The steady-state lamivudine pharmacokinetics among these patients was evaluated. METHODS: This overnight open-label pharmacokinetic study enrolled participants living with HIV and managed with CAPD. Lamivudine levels in blood serum and CAPD effluent samples were quantified using liquid chromatography coupled with a mass spectrometer. Pharmacokinetic measures were obtained through non-compartmental analysis. RESULTS: Twenty-eight participants were recruited with a median antiretroviral (ARV) drug duration of 8 (IQR,4.5-10.5) years and a CAPD duration of 13.3 (IQR,3.3-31.9) months. 14.3% (4/28) had detectable unsuppressed HIV-1 viral load in CAPD effluents. The majority (78,6%,22/28) of participants received a 50 mg dose, while 10.7% (3/28), and another 10.7% (3/28) received 75 mg and 300 mg dosages, respectively. Among those treated with 75 and 300 mg, 66.7% (2/3) and 33.3% (1/3) had detectable HIV-VL in CAPD, respectively. The peritoneal membrane characteristics and CAPD system strengths were variable across the entire study population. Lamivudine exposure was increased in blood serum (50 mg-AUC0-24 h, 651.3 ng/mL; 75 mg-AUC0-24 h, 677.84 ng/mL; 300 mg-AUC0-24 h, 3135.89 ng/mL) compared to CAPD effluents (50 mg-AUC0-24 h, 384.91 ng/mL; 75 mg-AUC0-24 h, 383.24 ng/mL; 300 mg-AUC0-24 h, 2001.60 ng/mL) among the entire study population. The Cmax (50 mg, 41.5 ng/mL; 75 mg, 53.2 ng/mL; 300 mg, 199.1 ng/mL) and Cmin (50 mg, 17.8 ng/mL; 75 mg, 16.4 ng/mL; 300 mg, 76.4 ng/mL) measured in serum were within the therapeutic levels. CONCLUSIONS: Steady-state lamivudine pharmacokinetic measures were variable among the entire study population. However, the total lamivudine exposure was within the therapeutic levels.
Asunto(s)
Infecciones por VIH , VIH-1 , Fallo Renal Crónico , Lamivudine , Diálisis Peritoneal , Humanos , Lamivudine/farmacocinética , Lamivudine/uso terapéutico , Lamivudine/administración & dosificación , Masculino , Persona de Mediana Edad , Femenino , VIH-1/efectos de los fármacos , Fallo Renal Crónico/terapia , Adulto , Infecciones por VIH/tratamiento farmacológico , ARN Viral/sangre , Fármacos Anti-VIH/farmacocinética , Fármacos Anti-VIH/uso terapéutico , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/administración & dosificación , Carga ViralRESUMEN
IL-35 is a recently discovered protein made up of IL-12α and IL-27ß chains. It is encoded by IL12A and EBI3 genes. Interest in researching IL-35 has significantly increased in recent years, as evidenced by numerous scientific publications. Diabetes is on the rise globally, causing more illness and death in developing countries. The International Diabetes Federation (IDF) reports that diabetes is increasingly affecting children and teenagers, with varying rates across different regions. Therefore, scientists seek new diabetes treatments despite the growth of drug research. Recent research aims to emphasize IL-35 as a critical regulator of diabetes, especially type 1 and autoimmune diabetes. This review provides an overview of recent research on IL-35 and its link to diabetes and its associated complications. Studies suggest that IL-35 can offer protection against type-1 diabetes and autoimmune diabetes by regulating macrophage polarization, T-cell-related cytokines, and regulatory B cells (Bregs). This review will hopefully assist biomedical scientists in exploring the potential role of IL-35-mediated immunotherapy in treating diabetes. However, further research is necessary to determine the exact mechanism and plan clinical trials.
Asunto(s)
Diabetes Mellitus Tipo 1 , Inmunoterapia , Interleucinas , Humanos , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/terapia , Inmunoterapia/métodos , Interleucinas/inmunología , Interleucinas/genética , Interleucinas/metabolismo , Animales , Linfocitos B Reguladores/inmunología , Macrófagos/inmunología , Macrófagos/metabolismoRESUMEN
The concept of drug repurposing is now widely utilized by biomedical scientists for drug discovery. An example of this is the use of selegiline (SEL), a monoamine oxidase inhibitor that was initially used for the management of depression but is now being considered for another purpose. This study compares the cytotoxic effects of SEL on different cancer cells. Further, the study explores the molecular mechanism of cell death, validating the possibility of its repurposing for cancer. Preliminary analysis of network pharmacological data was conducted in silico, followed by in vitro cytotoxicity tests on PC12, G361, MDA-MB231, MCF7, THP-1, and Hela cells under normoxic and hypoxic conditions, using the MTT assay. The mechanism of cell death was then confirmed by performing DAPI and FITC-conjugated Annexin V and Propidium Iodide (PI) staining assays. Additionally, ROS levels and PKC phosphorylation were also evaluated. In silico analysis has revealed that SEL is associated with ten genes linked to different cancer types. Specifically, SEL was most cytotoxic to neuronal pheochromocytoma, triple-negative human epithelial breast cancer cells, and ER+ and PR+ breast cancer cells. Furthermore, it was observed that this cell death occurred through ROS-independent apoptosis pathways. In addition, SEL was found to inhibit the phosphorylation of PKC, which may contribute to cell death. SEL induces apoptosis in breast cancer cells independently of reactive oxygen species and inhibits the phosphorylation of protein kinase C, which merits further exploration.
Asunto(s)
Apoptosis , Neoplasias de la Mama , Especies Reactivas de Oxígeno , Selegilina , Humanos , Selegilina/farmacología , Apoptosis/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismo , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Neoplasias de la Mama/metabolismo , Femenino , Línea Celular Tumoral , Inhibidores de la Monoaminooxidasa/farmacología , Animales , Ratas , Antineoplásicos/farmacología , Células PC12 , Células HeLa , Células MCF-7 , Reposicionamiento de MedicamentosRESUMEN
Around 2 million people are diagnosed with lung cancer annually, causing 20,000 deaths. Non-small cell carcinomas account for 80-85% of lung cancer cases. Over the last few decades, there has been an improved understanding of the chromosomal makeup of lung cancer. As a result, the clinical care and treatment of patients with advanced or metastatic non-small-cell lung cancer (NSCLC) have changed. This is possible due to advanced molecular techniques and chromosomal analysis, which have revealed persistent genetic abnormalities. Specific medications have increased the median survival time for NSCLC patients. Pulmonary pathology and oncology patients now receive personalized medication based on genetic abnormalities and other prognostic indicators. However, the diagnosis algorithms become complicated due to the various testing methods available. Consensus standards and recommendations have standardized NSCLC diagnostic testing. This article discusses the molecular genetic landscape of NSCLC and the latest therapy developments, focusing on clinically relevant changes using several schematic and tabular representations.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Humanos , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/genética , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/genéticaRESUMEN
The Advanced Glycation End Products (AGE) binding with its receptor can increase reactive oxygen species (ROS) generation through specific signaling mediators. The effect of superoxide (O2-) and O2- mediated ROS and reactive nitrogen species depends on their concentration and location of formation. Nitric oxide (NO) has anti-inflammatory and anticoagulant properties and a vasodilation effect, but NO can be deactivated by reacting with O2-. This reaction between NO and O2- produces the potent oxidant ONOO-. Therefore, ONOO-'s regulatory role in AGEs in diabetic cardiovascular complications must considered as a regulator of cardiovascular complications in diabetes.
RESUMEN
INTRODUCTION: The Bruguiera cylindrica L. is a mangrove plant that is typically found in coastal areas of Asia, including India. It has been known for its medicinal properties, which have been utilized for generations. For example, in Thailand, it has been used to treat wounds and diarrhoea, while in India, it has been effective in addressing diabetes, ulcers, and other health issues. This particular study sought to investigate the potential of B. cylindrica bark extract in reducing the symptoms of diabetes in rats. METHODS: In this study, we examined the potential of B. cylindrica bark extract as an inhibitor of α-amylase and α-glucosidase enzymes in vitro. We also evaluated the effects of the extract and Metformin on rats fed high-fat diets and measured their lipid profiles and biochemical parameters. Furthermore, we conducted a network pharmacology analysis to identify proteins and pathways involved in the amelioration of diabetes. RESULTS: Through metabolite profiling, we identified 58 compounds in B. cylindrica hydroalcoholic extract. These compounds include alkaloids, phenolics, flavonoids, and fatty acids. The extract was found to have a dose-dependent inhibition activity against α-amylase and α-glucosidase, with IC50 values similar to acarbose. In rats, oral administration of 200-400 mg/kg of B. cylindrica led to reduced blood glucose levels and normalized serum biochemical parameters. CONCLUSIONS: Bruguiera cylindrica bark may reduce blood sugar levels in rats with diabetes. The study found metabolites that interact with protein targets associated with different types of diabetes.
Asunto(s)
Diabetes Mellitus Experimental , Hipoglucemiantes , Farmacología en Red , Corteza de la Planta , Extractos Vegetales , alfa-Amilasas , Animales , Extractos Vegetales/farmacología , Hipoglucemiantes/farmacología , Ratas , Masculino , alfa-Amilasas/antagonistas & inhibidores , alfa-Amilasas/metabolismo , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/metabolismo , Corteza de la Planta/química , Inhibidores de Glicósido Hidrolasas/farmacología , alfa-Glucosidasas/metabolismo , Dieta Alta en Grasa , Metformina/farmacología , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Ratas Wistar , Relación Dosis-Respuesta a Droga , Ratas Sprague-DawleyRESUMEN
Rett syndrome (RTT) is a rare but dreadful X-linked genetic disease that mainly affects young girls. It is a neurological disease that affects nerve cell development and function, resulting in severe motor and intellectual disabilities. To date, no cure is available for treating this disease. In 90% of the cases, RTT is caused by a mutation in methyl-CpG-binding protein 2 (MECP2), a transcription factor involved in the repression and activation of transcription. MECP2 is known to regulate several target genes and is involved in different physiological functions. Mouse models exhibit a broad range of phenotypes in recapitulating human RTT symptoms; however, understanding the disease mechanisms remains incomplete, and many potential RTT treatments developed in mouse models have not shown translational effectiveness in human trials. Recent data hint that the zebrafish model emulates similar disrupted neurological functions following mutation of the mecp2 gene. This suggests that zebrafish can be used to understand the onset and progression of RTT pathophysiology and develop a possible cure. In this review, we elaborate on the molecular basis of RTT pathophysiology in humans and model organisms, including rodents and zebrafish, focusing on the zebrafish model to understand the molecular pathophysiology and the development of therapeutic strategies for RTT. Finally, we propose a rational treatment strategy, including antisense oligonucleotides, small interfering RNA technology and induced pluripotent stem cell-derived cell therapy.
Asunto(s)
Discapacidad Intelectual , Síndrome de Rett , Ratones , Animales , Femenino , Humanos , Síndrome de Rett/genética , Síndrome de Rett/terapia , Pez Cebra/genética , Regulación de la Expresión Génica , MutaciónRESUMEN
BACKGROUND: As per the recommendation of the United States Food and Drug Administration, more research is needed to determine the antibody titer against COVID-19 vaccination. OBJECTIVE: The study aimed to understand the relationship between the antibody titer to the demographics, infection severity, and cycle threshold (CT) values of confirmed COVID-19 patients. METHODS: Initially, we obtained consent from 185 populations and included sixty RT-PCRpositive COVID-19 patients from Kamrup District in the Northeast State of Assam, India. The vaccination status was recorded and tested for the level of serum immunoglobulin (IgG). The CT values, gender, and clinical symptoms-based scoring (CSBS) correlated with their IgG value. RESULTS: Around 48% of participants gained an antibody titer more than the threshold value and showed CT values between 18-25. Moreover, the maximum distributed score above the average was found between the CT values 18-25. CONCLUSION: The IgG titer value differs significantly amongst the vaccinated population, which may depend upon their genetic and demographic variability.
RESUMEN
Objective: To investigate Schima wallichii (S. wallichii) Choisy (Ternstroemiaceae) which is a well known plant of Sikkim in the Himalayan region, India. Methods: Therefore three major flavonoid enriched fractions (FPet.Ether, FChloroform and FEthylacetate) were isolated by petroleum ether chloroform and ethyl acetate successively. The reactive nitrogen species scavenging activity of the flavonoid fractions was established using biochemical assay to measure scavenging of 2, 2 diphenyl picrylhydrazyl (DPPH), nitric oxide (NO) and peroxinitrite. Results: FEthylacetate showed maximum scavenging activity: their IC50 being (7.33 ± 3.32), (7.11 ± 2.21), and (6.67 ± 2.23)μg/mL in DPPH, NO, peroxinitrite radical respectively. Presence of (57.32 ± 2.31) and (163.4 ±2.22) μg of flavonoids and phenolic compound in 1 mg of extract is assumed to be responsible for free radical scavenging activity. Conclusion: Taken together S. wallichii has potent free radical scavenging property indicating its importance in food supplement as a rich source of active flavonoid and phenolic compounds in ethyl acetate fraction which is responsible for its free radical scavenging as well as antioxidant activity.